Abstract 38P
Background
Tumor-infiltrating lymphocyte (TIL) therapy has emerged as a promising treatment for late-stage solid cancer patients. Most studies use fresh tumor fragments to expand TIL. Limited research exists on cryopreserving and long-term storing of tumors as TIL starting material. The aim of this study was to expand and characterize tumor-infiltrating lymphocytes (TILs) from tumor specimens stored in liquid nitrogen for over 12 months.
Methods
Tumors, resected from 20 patients with colorectal cancer, were immediately cut into small pieces and cryopreserved in liquid nitrogen for 14-20 months until use. Upon thawing tumor fragments were either placed in a TIL expansion media or were first subjected to enzymatic digestion. Serum-free culture media containing 500 units of IL2 was used for TIL expansion. CD3/CD28 antibodies were added at the start of the cultivation and every 7 days to activate TIL. After 10-22 days in culture, expanded TILs were characterized by phenotype. The ability of the expanded TIL to secrete interferon-ɣ (IFNɣ) was measured in the ELISPOT assay. T cell receptor (TCR) repertoire was analyzed on the starting tumor material and expanded TILs.
Results
The average storage time of the tumor starting material was 16 months. The success rate of TIL expansion was 50% and was the same when TILs were grown directly from small fragments or from single-cell tissue suspensions after enzymatic digestion. The mean percentage of CD3+ cells in TIL cultures was 85.31%. The mean percentage of CD4+ cells and CD8+ cells was 81.01% and 10.29% correspondingly. Regardless of the isolation method, 9 TIL cultures exhibited the high production of IFNgamma in the ELISPOT assay upon reactivation following cocultivation with phytohemagglutinin. Extended phenotype characterization and TCR repertoire analysis is ongoing.
Conclusions
Our study demonstrates the feasibility of using long-term cryopreserved tumor fragments for TIL expansion with further assessment of clonality, phenotyping and neoantigen specificity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Federal Medical Biological Agency funding for the «T-kletki» project, 123032900030-7.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
21P - DNAJC1 inhibit the ferroptosis of glioma cells through stabilizing GPX4 by competing with TRIM21
Presenter: Min Chao
Session: Poster session 07
Resources:
Abstract
22P - Pre-clinical development of CVGBM: A therapeutic mRNA-based multiepitope vaccine for glioblastoma
Presenter: Ronja Mülfarth
Session: Poster session 07
23P - Germline testing in a selected cohort of non-small cell lung cancer (NSCLC) patients: Final results from the INHERITY LC study
Presenter: Maria Zurera Berjaga
Session: Poster session 07
24P - Assessment of an AI algorithm to classify germline variants in the ATM cancer predisposition gene
Presenter: Nooshin Bayat
Session: Poster session 07
25P - NGS-based identification of novel hereditary breast/ovarian cancer genes in patients with clinical features of genetic predisposition
Presenter: Ekaterina Kuligina
Session: Poster session 07
26P - Multi-feature cell free DNA analysis and ensemble machine learning for early detection of cancer
Presenter: Seongmun Jeong
Session: Poster session 07
27P - Molecular insights on cutaneous melanoma hyperpigmentation and therapy resistance
Presenter: Elena Andreucci
Session: Poster session 07
28P - Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy
Presenter: Szonja Kovács
Session: Poster session 07
29P - Considering intra-patient response variability in clinical trials: Implications for treatment efficacy and survival
Presenter: Caryn Geady
Session: Poster session 07
Resources:
Abstract
30P - CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors
Presenter: Yang Zheng
Session: Poster session 07